A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.

A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.

To explore the feasibility and efficacy of docetaxel plus prednisone for Chinese population with metastatic castration refractory prostate cancer (mCRPC).A total of 228 patients recruited from 15 centers were randomized to receive 10 cycles of D3P arm (docetaxel: 75 mg/m2, intravenous infusion, ever...

Full description

Bibliographic Details
Main Authors: Tie Zhou, Shu-xiong Zeng, Ding-wei Ye, Qiang Wei, Xu Zhang, Yi-ran Huang, Zhang-qun Ye, Yong Yang, Wei Zhang, Ye Tian, Fang-jian Zhou, Jin Jie, Shi-ping Chen, Yan Sun, Li-ping Xie, Xing Yao, Yan-qun Na, Ying-hao Sun
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4307981?pdf=render

Internet

http://europepmc.org/articles/PMC4307981?pdf=render

Similar Items